Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.60 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 1/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2769697 | 1.00 | PREP (0.60) | PREPFKBP1ANPSR1NPC1RAB9A | |
| SCHEMBL5525089 | 0.92 | PREP (0.67) | PREPFKBP1ANPSR1ALDH1A1TSHR | |
| SCHEMBL4724457 | 0.92 | PREP (0.67) | PREPFKBP1ANPSR1ALDH1A1TSHR | |
| SCHEMBL630112 | 0.92 | PREP (0.67) | PREPFKBP1ANPSR1ALDH1A1TSHR | |
| SCHEMBL3578099 | 0.91 | FKBP1A (0.71) | PREPFKBP1ANPSR1ALDH1A1TSHR | |
| SCHEMBL630096 | 0.91 | FKBP1A (0.71) | PREPFKBP1ANPSR1ALDH1A1TSHR | |
| SCHEMBL631581 | 0.90 | FKBP1A (0.58) | PREPFKBP1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15215546 | 0.89 | PREP (0.52) | PREPFKBP1ANPSR1NPC1RAB9A | |
| SCHEMBL2760307 | 0.89 | PREP (0.52) | PREPFKBP1ANPSR1NPC1RAB9A | |
| SCHEMBL1694135 | 0.89 | PREP (0.52) | PREPFKBP1ANPSR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113631560-B | Azetidine benzodiazepine dimers and conjugates comprising the same for the treatment of cancer | 麦迪穆有限责任公司 | 2025-02-18 | — | — | CN | disclosed |
| US-12209099-B2 | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer | MEDIMMUNE LIMITED (GB) | 2025-01-28 | — | — | US | disclosed |
| EP-3938372-B1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LTD (GB) | 2023-10-25 | — | — | EP | disclosed |
| US-20220160881-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | MEDIMMUNE LIMITED (GB) | 2022-05-26 | — | — | US | disclosed |
| CN-113631560-A | Azetidino-benzodiazepine dimers and conjugates comprising same for the treatment of cancer | 麦迪穆有限责任公司 | 2021-11-09 | — | — | CN | disclosed |
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| EP-2240475-B1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| EP-2448946-B1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-8357707-B2 | 2-carboxamide cycloamino ureas | NOVARTIS AG (CH) | 2013-01-22 | — | — | US | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| US-6544976-B1 | Treating disorders characterized by neuronal damage caused by disease or trauma, such as Parkinson's disease, Alzheimer's disease, stroke, multiple sclerosis, amyotrophic lateral sclerosis, diabetic neuropathy and Bell's palsy. | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-08 | — | — | US | disclosed |
| WO-2001004091-A1 | NEUROTROPHIC 2-AZETIDINECARBOXYLIC ACID DERIVATIVES, AND RELATED COMPOSITIONS AND METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | PREP 1829/4885FKBP1A 543/4885NPSR1 718/4885 |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | PIK3C3, PRKACA, UACA | PREP 1576/4885FKBP1A 1738/4885NPSR1 4660/4885 |
| US-20220160881-A1 | AZETIDOBENZODIAZEPINE DIMERS AND CONJUGATES COMPRISING THEM FOR USE IN THE TREATMENT OF CANCER | BCR, UGT2B17, BCL6B | PREP 2494/4885FKBP1A 1839/4885NPSR1 572/4885 |
| US-12209099-B2 | Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer | BCR, UGT2B17, BCL6B | PREP 2494/4885FKBP1A 1839/4885NPSR1 572/4885 |
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | PREP 4306/4885FKBP1A 1575/4885NPSR1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.